Skip to main content
. 2023 Mar 13;43(8):2763–2776. doi: 10.1007/s10792-023-02675-5

Table 3.

Interventions to treat neovascularization

Intervention Number of eyes (%)
Intravitreal bevacizumab before or within the first week from presentation

47 (70.1%)

 BVT 14 (77.8%)

 TSCPC 24 (66.7%)

 Nil 5 (62.5%)

 PPV 3 (100%)

 Trab + MMC 1 (50%)
Intravitreal bevacizumab before or within the first month from presentation

54 (80.6%)

 BVT 16 (88.9%)

 TSCPC 29 (80.6%)

 Nil 5 (62.5%)

 PPV 3 (100%)

 Trab + MMC 1 (50%)
PRP before or within the first week of presentation

28 (41.8%)

 BVT 8 (44.4%)

 TSCPC 14 (38.9%)

 Nil 3 (37.5%)

 PPV 3 (100%)
PRP before or within the first month from presentation

42 (62.7%)

 BVT 13 (72.2%)

 TSCPC 22 (61.1%)

 Nil 4 (50.0%)

 PPV 3 (100%)
PRP prior to NVG diagnosis without additional top-up 7 (10.4%)
Postoperative PRP top-up 27 (40%)
Cryotherapy 1 month post-diagnosis 1 (1.5%)

VEGFI vascular endothelial growth factor inhibitor, PRP pan-retinal photocoagulation, BVT Baerveldt tube, TSCPC trans-scleral cyclophotocoagulation, PPV pars plana vitrectomy, Trab + MMC trabeculectomy with mitomycin C